XY Therapeutics ApS: Financial statements 2024
CVR: 41120681
Source: annual report 2024, Danish Business Authority
01/07/2023 – 30/06/2024
XY Therapeutics ApS (CVR 41120681) has filed annual accounts for 2024. In 2024, the company reported a gross profit of DKK 2,680,629 and a net result of DKK -1,369,854 compared with DKK -1,152,205 the year before. That is an increase of 641.3% compared with the year before. Equity in the 2024 report amounted to DKK -7,397,646. The company had 1 employee in the financial year.
- Gross Profit
- DKK 2,680,629
- Profit/Loss
- DKK -1,369,854
- Equity
- DKK -7,397,646
- Total Assets
- DKK 4,898,727
- Employees
- 1
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2024 | - | 2.7M | -1.4M | -7.4M | 1 |
| 2023 | - | 362K | -1.2M | -6M | 2 |
| 2022 | - | 627K | -2.4M | -4.9M | 2 |
Official annual report
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningEvents in 2024
XY Therapeutics ApS has published its annual report for 2023. Gross profit came to DKK 361,632, and the net result was DKK -1,152,205.
About XY Therapeutics ApS
XY Therapeutics ApS is a Danish company of the type Anpartsselskab based in Charlottenlund, founded in 2020. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named Fertilitypro ApS. The management consists of Martin Blomberg Jensen. The company is owned by Holding Fertility4U ApS. The company has 2 employees (2026). In 2025, the company reported a gross profit of DKK 3,676,788 and a net result of DKK -2,096,400 compared with DKK -1,369,854 the year before. Equity in the 2025 report amounted to DKK -9,494,046.